Monika Tomaszuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Monika Tomaszuk has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Anna Sowa-Staszczak
7 shared publicationsMonika Buziak-Bereza
6 shared publicationsAgnieszka Stefanska
4 shared publications- Alicja Hubalewska-Dydejczyk
Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland
4 shared publications - Aleksandra Gilis-Januszewska
Chair and Department of Endocrinology, Jagiellonian University Medical College
3 shared publications Alicja Hubalewska-Dydejczyk
3 shared publications
Latest Publications
- Open Access
- 31 March 2017
- Published by Slovenian Society for Stereology and Quantitative Image Analysis in Image Analysis and Stereology
- Vol. 36 (1) , 35-41
APPLICATION OF IMAGE ANALYSIS METHODS FOR ISOCENTER QUALITY ASSURANCE IN RADIOTHERAPY
One of the major procedures for testing the geometrical accuracy of devices used in radiotherapy treatments is the test of the geometrical position of the radiation isocenter. The importance of the test reflects the fact that geometrical position of the radiation isocenter generally affects the tumor targeting. At present the geometric accuracy is assessed with the Winston-Lutz test which checks the position of an image of a ball marker with the respect to the center of the radiation field as projected on a detector plane. Obviously, determination of coordinates of a single marker is not sufficient to fully account for a complicated geometry of a therapeutic device. The purpose of the study was to design a new image analysis tool to better determine the isocenter. The proposed automated procedure for determining isocenter position uses projection data acquired for a special cube phantom. The projection images of a phantom are acquired for various angles of rotation of the gantry. A procedure is proposed to extract some geometric characteristics of a therapeutic device from the projection images.
- 31 March 2017
- Published by Slovenian Society for Stereology and Quantitative Image Analysis in Image Analysis and Stereology
- Vol. 36 (1) , 35-41
Open AccessAPPLICATION OF IMAGE ANALYSIS METHODS FOR ISOCENTER QUALITY ASSURANCE IN RADIOTHERAPY
One of the major procedures for testing the geometrical accuracy of devices used in radiotherapy treatments is the test of the geometrical position of the radiation isocenter. The importance of the test reflects the fact that geometrical position of the radiation isocenter generally affects the tumor targeting. At present the geometric accuracy is assessed with the Winston-Lutz test which checks the position of an image of a ball marker with the respect to the center of the radiation field as projected on a detector plane. Obviously, determination of coordinates of a single marker is not sufficient to fully account for a complicated geometry of a therapeutic device. The purpose of the study was to design a new image analysis tool to better determine the isocenter. The proposed automated procedure for determining isocenter position uses projection data acquired for a special cube phantom. The projection images of a phantom are acquired for various angles of rotation of the gantry. A procedure is proposed to extract some geometric characteristics of a therapeutic device from the projection images.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Combined therapy PRRT with long acting somatostatin analogue: results of 7 years' experience
Introduction: The aim of this study was to assess the survival rate of patients with disseminated or inoperable neuroendocrine tumors (NETs) after PRRT with the use of 90Y-DOTATATE combined with long acting somatostatin analogue. Materials and methods: 72 patients were treated with PRRT in our Department. The 90Y-DOTATATE therapeutic activity was calculated per total body surface area up to a total of 7.4 GBq/m2 administrated in three to five cycles, repeated every 1–9 weeks. After PRRT, patients have been further treated with cold long acting somatostatin analogues to the progression of the disease. Results: Out of 72 90Y-DOTATATE treated patients, 22 died after completing the therapy, among them two due to myocardial infarction. After 12 month follow-up, stabilization of disease was observed in 63%, partial remission in 25%, and progression in 12% in this group of patients. The progression free survival (PFS) was found to be 41.27 months and the event-free survival (EFS) – 37.73 months. The median overall survival (OS) was not reached. According to the literature (Ćwikła et al. 2010) in group of 57 patients treated by 90Y-DOTATATE up to a cumulative activity of 15.2 GBq PFS and OS was about 17 and 22 months respectively. During follow-up, transient decrease of PLT, WBC and haemoglobin values was observed. An increase of creatinine level and decrease of GFR values in the observation period were found, but these were clinically insignificant symptoms of transient nephrotoxicity. Conclusion: PRRT and further treatment with long acting somatostatin analogues may extended the survival of disseminated patients with NETs. Long-term patients benefit in the form of symptomatic relief and tumour mass reduction after 90Y-DOTATATE therapy was also observed.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Combined therapy PRRT with long acting somatostatin analogue: results of 7 years' experience
Introduction: The aim of this study was to assess the survival rate of patients with disseminated or inoperable neuroendocrine tumors (NETs) after PRRT with the use of 90Y-DOTATATE combined with long acting somatostatin analogue. Materials and methods: 72 patients were treated with PRRT in our Department. The 90Y-DOTATATE therapeutic activity was calculated per total body surface area up to a total of 7.4 GBq/m2 administrated in three to five cycles, repeated every 1–9 weeks. After PRRT, patients have been further treated with cold long acting somatostatin analogues to the progression of the disease. Results: Out of 72 90Y-DOTATATE treated patients, 22 died after completing the therapy, among them two due to myocardial infarction. After 12 month follow-up, stabilization of disease was observed in 63%, partial remission in 25%, and progression in 12% in this group of patients. The progression free survival (PFS) was found to be 41.27 months and the event-free survival (EFS) – 37.73 months. The median overall survival (OS) was not reached. According to the literature (Ćwikła et al. 2010) in group of 57 patients treated by 90Y-DOTATATE up to a cumulative activity of 15.2 GBq PFS and OS was about 17 and 22 months respectively. During follow-up, transient decrease of PLT, WBC and haemoglobin values was observed. An increase of creatinine level and decrease of GFR values in the observation period were found, but these were clinically insignificant symptoms of transient nephrotoxicity. Conclusion: PRRT and further treatment with long acting somatostatin analogues may extended the survival of disseminated patients with NETs. Long-term patients benefit in the form of symptomatic relief and tumour mass reduction after 90Y-DOTATATE therapy was also observed.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
99mTc-GLP-1 scintigraphy, an efficient method for the detection of insulinoma: results of 3 years' experience
Introduction: The aim of this study was to assess the diagnostic efficiency of [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 scintigraphy in the detection of hardly detectable or not diagnosed by other available method insulinomas. Materials and methods: 37 patients (24 women and 13 men, mean age 46.5±17.8 years, min. 16.0 years, max. 77.0 years) were enrolled in this study. There were 32 patients with clinical and biochemical symptoms and signs of insulinoma, one patient with malignant insulinoma, one patient with suspected local recurrence of malignant insulinoma (MEN1) and three with nesidioblastosis. In all patients prior examinations (CT/MRI/SRS) were negative or equivocal. The lyophilized kit provided by Radioisotope Center POLATOM was used for preparing the tracer. Whole-body and SPECT/CT scans at two points time points were performed. Results: In 27 cases with suspicion of insulinoma a focal uptake in the pancreas was found – classified as insulinoma. In four negative cases reactive hypoglycaemia was diagnosed. In one case exogenous stimulation of insulin level by patient was revealed. In one case with malignant insulinoma pathological accumulation of the tracer was found only in the region of local recurrence. The GLP-1 study was negative in the other malignant insulinoma patient. In two patients with suspected nesidioblastosis diffuse accumulation of tracer was observed. In one case with suspicion of nesidioblastosis, a focal accumulation of the tracer was observed – histopathology revealed coexistence of insulinoma and nesidioblastosis. Conclusion: 99mTc-GLP-1 receptor scintigraphy is a promising diagnostic tool for patients with clinical symptoms of insulinoma. It enables the localization of even very small tumours with excellent sensitivity and proper imaging is the most important step for successful surgery and complete patient recovery.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
99mTc-GLP-1 scintigraphy, an efficient method for the detection of insulinoma: results of 3 years' experience
Introduction: The aim of this study was to assess the diagnostic efficiency of [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 scintigraphy in the detection of hardly detectable or not diagnosed by other available method insulinomas. Materials and methods: 37 patients (24 women and 13 men, mean age 46.5±17.8 years, min. 16.0 years, max. 77.0 years) were enrolled in this study. There were 32 patients with clinical and biochemical symptoms and signs of insulinoma, one patient with malignant insulinoma, one patient with suspected local recurrence of malignant insulinoma (MEN1) and three with nesidioblastosis. In all patients prior examinations (CT/MRI/SRS) were negative or equivocal. The lyophilized kit provided by Radioisotope Center POLATOM was used for preparing the tracer. Whole-body and SPECT/CT scans at two points time points were performed. Results: In 27 cases with suspicion of insulinoma a focal uptake in the pancreas was found – classified as insulinoma. In four negative cases reactive hypoglycaemia was diagnosed. In one case exogenous stimulation of insulin level by patient was revealed. In one case with malignant insulinoma pathological accumulation of the tracer was found only in the region of local recurrence. The GLP-1 study was negative in the other malignant insulinoma patient. In two patients with suspected nesidioblastosis diffuse accumulation of tracer was observed. In one case with suspicion of nesidioblastosis, a focal accumulation of the tracer was observed – histopathology revealed coexistence of insulinoma and nesidioblastosis. Conclusion: 99mTc-GLP-1 receptor scintigraphy is a promising diagnostic tool for patients with clinical symptoms of insulinoma. It enables the localization of even very small tumours with excellent sensitivity and proper imaging is the most important step for successful surgery and complete patient recovery.
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
Six-years experience in the treatment of the neuroendocrine tumors with the use of peptide receptor radionuclide therapy (PRRT)
Introduction: The aim of this study was to assess the efficacy of peptide receptor radionuclide therapy (PRRT) with the use of 90Y-DOTATATE and the survival rate of patients with disseminated or non-operable neuroendocrine tumors (NETs). Methods: In the time period from June 2006 to October 2012, 70 patients were treated with PRRT in our department. The 90Y-DOTATATE therapeutic activity was calculated per total body surface area up to a total of 7.4 GBq/m2 administrated in three to five cycles, repeated every 4–9 weeks. Before and after the therapy, blood tests for hematology, kidney and liver function were performed. After PRRT, patients have been further treated with cold long acting somatostatin analogues (Sandostatin LAR) to the progression of the disease. Results: Out of 70 90Y-DOTATATE treated patients, 22 died after completing the therapy, among them two due to myocardial infarction. After 12-month follow-up, stabilization of the disease was observed in 63%, partial remission in 25%, and progression in 12% in this group of patients. The progression-free survival (PFS) was found to be 41.27 months and the event-free survival (EFS) 37.73 months. The median overall survival (OS) was not reached. During follow-up, transient decrease in PLT, WBC and hemoglobin values was observed. A increase in creatinine level and decrease in GFR values over observation period were found, but these were clinically insignificant symptoms of transient nephrotoxicity. Summary: Long-term patients benefit in the form of long survival rate, symptomatic relief and tumor mass reduction after 90Y-DOTATATE therapy was observed. PRRT is safety method and may extend the survival of disseminated patients with NETs.
- 1 April 2013
- Published by Bioscientifica in Endocrine Abstracts
Six-years experience in the treatment of the neuroendocrine tumors with the use of peptide receptor radionuclide therapy (PRRT)
Introduction: The aim of this study was to assess the efficacy of peptide receptor radionuclide therapy (PRRT) with the use of 90Y-DOTATATE and the survival rate of patients with disseminated or non-operable neuroendocrine tumors (NETs). Methods: In the time period from June 2006 to October 2012, 70 patients were treated with PRRT in our department. The 90Y-DOTATATE therapeutic activity was calculated per total body surface area up to a total of 7.4 GBq/m2 administrated in three to five cycles, repeated every 4–9 weeks. Before and after the therapy, blood tests for hematology, kidney and liver function were performed. After PRRT, patients have been further treated with cold long acting somatostatin analogues (Sandostatin LAR) to the progression of the disease. Results: Out of 70 90Y-DOTATATE treated patients, 22 died after completing the therapy, among them two due to myocardial infarction. After 12-month follow-up, stabilization of the disease was observed in 63%, partial remission in 25%, and progression in 12% in this group of patients. The progression-free survival (PFS) was found to be 41.27 months and the event-free survival (EFS) 37.73 months. The median overall survival (OS) was not reached. During follow-up, transient decrease in PLT, WBC and hemoglobin values was observed. A increase in creatinine level and decrease in GFR values over observation period were found, but these were clinically insignificant symptoms of transient nephrotoxicity. Summary: Long-term patients benefit in the form of long survival rate, symptomatic relief and tumor mass reduction after 90Y-DOTATATE therapy was observed. PRRT is safety method and may extend the survival of disseminated patients with NETs.
- Open Access
- 8 February 2013
- Published by VM Media Group sp. z o.o in Nuclear Medicine Review
- Vol. 16 (1) , 9-16
Optimization of image reconstruction method for SPECT studies performed using [99mTc-EDDA/HYNIC] octreotate in patients with neuroendocrine tumors
Somatostatin receptor scintigraphy (SRS) is a useful tool in the assessment of GEP-NET (gastroenteropancreatic neuroendocrine tumor) patients. The choice of appropriate settings of image reconstruction parameters is crucial in interpretation of these images. The aim of the study was to investigate how the GEP NET lesion signal to noise ratio (TCS/TCB) depends on different reconstruction settings for Flash 3D software (Siemens). SRS results of 76 randomly selected patients with confirmed GEP-NET were analyzed. For SPECT studies the data were acquired using standard clinical settings 3-4 h after the injection of 740 MBq 99mTc-[EDDA/HYNIC] octreotate. To obtain final images the OSEM 3D Flash reconstruction with different settings and FBP reconstruction were used. First, the TCS/TCB ratio in voxels was analyzed for different combinations of the number of subsets and the number of iterations of the OSEM 3D Flash reconstruction. Secondly, the same ratio was analyzed for different parameters of the Gaussian filter (with FWHM = 2-4 times greater from the pixel size). Also the influence of scatter correction on the TCS/TCB ratio was investigated. With increasing number of subsets and iterations, the increase of TCS/TCB ratio was observed. With increasing settings of Gauss [FWHM coefficient] filter, the decrease of TCS/TCB ratio was reported. The use of scatter correction slightly decreases the values of this ratio. OSEM algorithm provides a meaningfully better reconstruction of the SRS SPECT study as compared to the FBP technique. A high number of subsets improves image quality (images are smoother). Increasing number of iterations gives a better contrast and the shapes of lesions and organs are sharper. The choice of reconstruction parameters is a compromise between image qualitative appearance and its quantitative accuracy and should not be modified when comparing multiple studies of the same patient.
- 8 February 2013
- Published by VM Media Group sp. z o.o in Nuclear Medicine Review
- Vol. 16 (1) , 9-16
Open AccessOptimization of image reconstruction method for SPECT studies performed using [99mTc-EDDA/HYNIC] octreotate in patients with neuroendocrine tumors
Somatostatin receptor scintigraphy (SRS) is a useful tool in the assessment of GEP-NET (gastroenteropancreatic neuroendocrine tumor) patients. The choice of appropriate settings of image reconstruction parameters is crucial in interpretation of these images. The aim of the study was to investigate how the GEP NET lesion signal to noise ratio (TCS/TCB) depends on different reconstruction settings for Flash 3D software (Siemens). SRS results of 76 randomly selected patients with confirmed GEP-NET were analyzed. For SPECT studies the data were acquired using standard clinical settings 3-4 h after the injection of 740 MBq 99mTc-[EDDA/HYNIC] octreotate. To obtain final images the OSEM 3D Flash reconstruction with different settings and FBP reconstruction were used. First, the TCS/TCB ratio in voxels was analyzed for different combinations of the number of subsets and the number of iterations of the OSEM 3D Flash reconstruction. Secondly, the same ratio was analyzed for different parameters of the Gaussian filter (with FWHM = 2-4 times greater from the pixel size). Also the influence of scatter correction on the TCS/TCB ratio was investigated. With increasing number of subsets and iterations, the increase of TCS/TCB ratio was observed. With increasing settings of Gauss [FWHM coefficient] filter, the decrease of TCS/TCB ratio was reported. The use of scatter correction slightly decreases the values of this ratio. OSEM algorithm provides a meaningfully better reconstruction of the SRS SPECT study as compared to the FBP technique. A high number of subsets improves image quality (images are smoother). Increasing number of iterations gives a better contrast and the shapes of lesions and organs are sharper. The choice of reconstruction parameters is a compromise between image qualitative appearance and its quantitative accuracy and should not be modified when comparing multiple studies of the same patient.
- 24 August 2012
- Published by Springer Nature
- Vol. 194, 479-485
PRRT as Neoadjuvant Treatment in NET
This chapter describes the possibility of using peptide receptor radionuclide therapy (PRRT) as neoadjuvant treatment. PRRT is acknowledged to be a palliative treatment. Recently it has been reported that tumor size decrease followed by surgical intervention might be achieved in patients with neuroendocrine tumors (NETs) treated with somatostatin analogs labeled with beta emitters. Such outcome of therapy has been described in a relatively small group of patients. In those patients, the treatment enabled total or partial excision of the tumor, also with liver metastases. Reduction of tumor dimensions or total excision of the tumor corresponded with prolongation of overall survival. The discussed papers on this subject differ in details of treatment (utilization of various isotopes, total activity of the isotope, or combination with radiosensitizing chemotherapy). The chapter presents a brief review of recently published manuscripts.
- 24 August 2012
- Published by Springer Nature
- Vol. 194, 479-485
PRRT as Neoadjuvant Treatment in NET
This chapter describes the possibility of using peptide receptor radionuclide therapy (PRRT) as neoadjuvant treatment. PRRT is acknowledged to be a palliative treatment. Recently it has been reported that tumor size decrease followed by surgical intervention might be achieved in patients with neuroendocrine tumors (NETs) treated with somatostatin analogs labeled with beta emitters. Such outcome of therapy has been described in a relatively small group of patients. In those patients, the treatment enabled total or partial excision of the tumor, also with liver metastases. Reduction of tumor dimensions or total excision of the tumor corresponded with prolongation of overall survival. The discussed papers on this subject differ in details of treatment (utilization of various isotopes, total activity of the isotope, or combination with radiosensitizing chemotherapy). The chapter presents a brief review of recently published manuscripts.
- 1 July 2012
- Published by Elsevier in Clinical Imaging
- Vol. 36 (4) , 360-364
Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?
- 1 July 2012
- Published by Elsevier in Clinical Imaging
- Vol. 36 (4) , 360-364
Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?
- 1 January 2011
- Vol. 62 (5) , 392-400
Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours.
The aim of this study was to assess the efficacy and toxicity of peptide receptor radionuclide therapy (PRRT) with the use of the high affinity somatostatin receptor subtype 2 analogue, (90)Y labelled Tyr3-octreotate, ((90)Y-DOTATATE) in neuroendocrine tumours (NETs). 46 patients with disseminated or non-operable NET were enrolled in this study. The (90)Y-DOTATATE therapeutic activity was calculated per total body surface area up to a total of 7.4 GBq/m(2) administered in three to five cycles, repeated every four to nine weeks. Before and after the therapy, blood tests for haematology, kidney and liver function, and chromogranin A were performed. Out of 46 (90)Y-DOTATATE treated patients, one died before completing the therapy and 16 died after completing the therapy, among them one due to myocardial infarction. After 12 month follow-up, stabilisation of disease was observed in 47%, partial remission in 31%, and progression in 9% of the 45 patients who completed the therapy. Five patients died before completion of 12 months of follow-up. One of the patients died due to myocardial infarction. In one case, the information after 12 months is incomplete. The progression free survival was 37.4 months. During 12 months follow-up, transient decrease of PLT, WBC and haemoglobin values was observed. A transient increase of creatinine level (within normal ranges) and decrease of GFR values were found. NETs (90)Y-DOTATATE therapy results in symptomatic relief and tumour mass reduction. The mild critical organ toxicity does not limit the PRRT of NETs.
- 1 January 2011
- Vol. 62 (5) , 392-400
Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours.
The aim of this study was to assess the efficacy and toxicity of peptide receptor radionuclide therapy (PRRT) with the use of the high affinity somatostatin receptor subtype 2 analogue, (90)Y labelled Tyr3-octreotate, ((90)Y-DOTATATE) in neuroendocrine tumours (NETs). 46 patients with disseminated or non-operable NET were enrolled in this study. The (90)Y-DOTATATE therapeutic activity was calculated per total body surface area up to a total of 7.4 GBq/m(2) administered in three to five cycles, repeated every four to nine weeks. Before and after the therapy, blood tests for haematology, kidney and liver function, and chromogranin A were performed. Out of 46 (90)Y-DOTATATE treated patients, one died before completing the therapy and 16 died after completing the therapy, among them one due to myocardial infarction. After 12 month follow-up, stabilisation of disease was observed in 47%, partial remission in 31%, and progression in 9% of the 45 patients who completed the therapy. Five patients died before completion of 12 months of follow-up. One of the patients died due to myocardial infarction. In one case, the information after 12 months is incomplete. The progression free survival was 37.4 months. During 12 months follow-up, transient decrease of PLT, WBC and haemoglobin values was observed. A transient increase of creatinine level (within normal ranges) and decrease of GFR values were found. NETs (90)Y-DOTATATE therapy results in symptomatic relief and tumour mass reduction. The mild critical organ toxicity does not limit the PRRT of NETs.
- 1 January 2010
- Vol. 13 (2) , 55-8
Biokinetics of ¹³¹I after endogenous and exogenous stimulation of TSH in patients with DTC.
The effective radioiodine treatment of patients with DTC is possible only after raising the TSH value over 30 μUI/ml. This effect might be obtained by either endogenous or exogenous stimulation. The aim of this study was to evaluate differences in (131)I biokinetics of selected regions of interest (ROIs) in cases of endogenous and exogenous stimulation. Two groups of 50 patients were enrolled in the study. All patients were treated with 3.7 GBq of ¹³¹I; the first group after thyroid hormone withdrawal (THW), the second group after rhTSH administration (rhTSH). On the basis of post-treatment images, the uptake ratios over selected ROIs (thyroid remnants, mediastinum, liver, stomach, abdomen, and whole-body) were compared between groups. In the case of uptake over the whole-body and the liver, statistically significant higher values were received for the THW group. For the remaining regions, the differences between groups were statistically insignificant, but uptake ratios in the rhTSH group were generally numerically lower compared to the THW group. The revealed difference in radioiodine biokinetics after thyroid hormone withdrawal or administration of recombinant human TSH may influence many important aspects of patients with DTC treatment, such as the choice of proper therapeutic scheme, the cost of therapy, and the dose assessment.
- 1 January 2010
- Vol. 13 (2) , 55-8
Biokinetics of ¹³¹I after endogenous and exogenous stimulation of TSH in patients with DTC.
The effective radioiodine treatment of patients with DTC is possible only after raising the TSH value over 30 μUI/ml. This effect might be obtained by either endogenous or exogenous stimulation. The aim of this study was to evaluate differences in (131)I biokinetics of selected regions of interest (ROIs) in cases of endogenous and exogenous stimulation. Two groups of 50 patients were enrolled in the study. All patients were treated with 3.7 GBq of ¹³¹I; the first group after thyroid hormone withdrawal (THW), the second group after rhTSH administration (rhTSH). On the basis of post-treatment images, the uptake ratios over selected ROIs (thyroid remnants, mediastinum, liver, stomach, abdomen, and whole-body) were compared between groups. In the case of uptake over the whole-body and the liver, statistically significant higher values were received for the THW group. For the remaining regions, the differences between groups were statistically insignificant, but uptake ratios in the rhTSH group were generally numerically lower compared to the THW group. The revealed difference in radioiodine biokinetics after thyroid hormone withdrawal or administration of recombinant human TSH may influence many important aspects of patients with DTC treatment, such as the choice of proper therapeutic scheme, the cost of therapy, and the dose assessment.
- 1 January 2010
- Vol. 67 (4) , 314-7
[Fusion SPECT/CT in clinical practice].
Fusion consists in a combination of images obtained using different diagnostic techniques, usually functional (SPECT, PET) and structural (CT, MR) imaging. It may be performed as a software fusion of images obtained not the same time by different devices or as a hardware fusion of images obtained the same time using as a hybrid system enabling both the functional and structural imaging (SPECT/CT, PET/CT). Fusion enables precise anatomical location of lesions detected by SPECT, functional verification of lesions found by CT. It is a useful tool in the assessment of effectiveness and dosimetry for radioisotopic therapy. Additionally fusion of functional and structural examinations reduces diagnostic difficulties appearing in independent interpretation. In spite of inconveniences resulting from technical aspects of software fusion (positioning differences, spontaneous movements of internal organs) it is more and more commonly used in clinical practice in centers not possessing hybrid systems.
- 1 January 2010
- Vol. 67 (4) , 314-7
[Fusion SPECT/CT in clinical practice].
Fusion consists in a combination of images obtained using different diagnostic techniques, usually functional (SPECT, PET) and structural (CT, MR) imaging. It may be performed as a software fusion of images obtained not the same time by different devices or as a hardware fusion of images obtained the same time using as a hybrid system enabling both the functional and structural imaging (SPECT/CT, PET/CT). Fusion enables precise anatomical location of lesions detected by SPECT, functional verification of lesions found by CT. It is a useful tool in the assessment of effectiveness and dosimetry for radioisotopic therapy. Additionally fusion of functional and structural examinations reduces diagnostic difficulties appearing in independent interpretation. In spite of inconveniences resulting from technical aspects of software fusion (positioning differences, spontaneous movements of internal organs) it is more and more commonly used in clinical practice in centers not possessing hybrid systems.